Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea-Reference-Cited by-同舟云学术

Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea

Published:2022-12-02 Issue:1 Volume:10 Page:131-143
ISSN:2199-1154
Container-title:Drugs - Real World Outcomes
language:en
Short-container-title:Drugs - Real World Outcomes

Author:

Molife Cliff^ORCID,Cho Jae Min^ORCID,Lapthorn Jennifer^ORCID,Kang Min Ju,D’yachkova Yulia^ORCID,Kim Sangmi,Colman Sam,Kim Saerom,Szende Agota,Park Ji Hyun,Ahn Hee Kyung^ORCID,Hong Min Hee^ORCID,Taipale Kaisa-Leena,Kim Hye Ryun^ORCID

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40801-022-00344-0.pdf

Reference33 articles.

1. Hong S, Won YJ, Lee JJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2018. Cancer Res Treat. 2021;53(2):301–15.

2. Jeon SM, Kwon J-W, Choi SH, et al. Economic burden of lung cancer: a retrospective cohort study in South Korea, 2002–2015. PLoS ONE. 2019;14(2): e0212878.

3. Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985–93.

4. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892.

5. Planchard D, Popat S, Kerr K, et al. Correction to: “Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.” Ann Oncol. 2019;30(5):863–70.